ArticleCardiovascular diagnosis and therapy2026
Prognostic value of early cardiac magnetic resonance first-pass perfusion assessment of microcirculatory dysfunction for acute rejection after heart transplantation.
Article in Cardiovascular diagnosis and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute rejection (AR) remains a major obstacle to success after heart transplantation (HT). Impaired microcirculatory function is linked to a higher risk of AR. The value of cardiac magnetic resonance (CMR) resting first‑pass perfusion imaging for evaluating microcirculatory function to predict subsequent AR after HT remains unclear. We aimed to evaluate the prognostic value of CMR resting first‑pass perfusion parameters measured early after HT for AR. Methods: This single-center retrospective study analyzed data from 79 HT recipients, including 21 with AR [HT (AR+)] and 58 without AR [HT (AR-)], and 32 healthy volunteers. CMR examination was performed at 3 months after HT to assess myocardial perfusion. Resting first-pass perfusion parameters, including time to peak myocardial signal intensity (TTM), Upslope, and maximum signal intensity (MaxSI) were analyzed. Univariable and multivariable Cox regression analyses were performed to identify predictors of AR within 2 years after HT. Incremental prognostic value was evaluated using C-index, continuous net reclassification index (NRI), and integrated discrimination improvement (IDI). P value <0.05 was considered statistically significant. Results: During a median follow‑up of 24 months, 21 HT recipients (26.6%) experienced AR. Patients with AR showed significantly longer TTM, lower Upslope and MaxSI at 3 months after HT compared with non‑AR patients and controls (all P<0.001). TTM [adjusted hazard ratio (aHR): 1.07 (1.04, 1.10), P<0.001], Upslope [aHR: 0.78 (0.71, 0.86), P<0.001], and MaxSI [aHR: 0.97 (0.95, 0.98), P<0.001] were independent predictors of AR after adjusting for age and body mass index (BMI). Adding TTM, Upslope, and MaxSI individually to the clinical model (age + BMI) significantly improved discriminant and reclassification ability for risk of AR (C‑index: 0.803, 0.889, 0.869 Conclusions: CMR resting first‑pass perfusion parameters acquired early after HT that reflect microcirculatory dysfunction are independent prognostic markers of AR within 2 years and provide incremental prognostic value over clinical variables to guide personalized post‑transplant management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.